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Fabry disease is a rare X-linked disorder caused by an alpha-galactosidase enzyme 
deficiency, which leads to a progressive lysosomal glycosphingolipids accumulation, mainly 
globotriaosylceramide, in multiple organism tissues including the eye. 
This case series describes the first ophthalmological Colombian report of Fabry disease 
highlighting the importance of ocular signs as markers of the disease, useful in diagnosis 
and treatment to avoid long-term complications that lead to a morbi-mortality increment. 
We describe five cases of Fabry disease from Bogotá, Colombia, including a complete 
clinical history, ophthalmologic, optometric examination, and photographs. We found that all 
patients had refractive defects and that in all cases corneal verticillata pattern was found. 
Four patients presented with posterior capsule lens brown-beige deposits and four patients 
had conjunctival and retinal tortuous vessels. 
A complete ophthalmologic examination is important for prompt diagnosis, which is key to 
starting a multidisciplinary treatment and reducing morbi-mortality.
Keywords: Fabry disease; alpha-Galactosidase; lysosomal storage diseases; corneal 
opacity; retinal vessels; lens capsule, crystalline.
Manifestaciones oculares de la enfermedad de Fabry en pacientes colombianos
La enfermedad de Fabry es un raro trastorno ligado al cromosoma X causado por 
deficiencia de la enzima alfa-galactosidasa y la consiguiente y progresiva acumulación 
lisosómica de glucoesfingolípidos, especialmente la globotriaosilceramida, en múltiples 
tejidos del organismo, incluido el ojo. 
En este reporte se presenta la primera serie de casos de manifestaciones oculares de la 
enfermedad de Fabry en Colombia, resaltando la importancia de los signos oculares como 
ayuda para el diagnóstico temprano. 
Se presentan cinco casos de la enfermedad en Bogotá y se da cuenta de las historias 
clínicas y los exámenes oftalmológicos y de optometría, y se incluyen fotografías. En 
todos los pacientes se hallaron errores de refracción y se evidenció el patrón de córnea 
verticillata. Cuatro pacientes presentaban depósitos de color café y castaño claro en la 
cápsula posterior del cristalino, y cuatro tenían tortuosidad vascular conjuntival y retiniana. 
El examen oftalmológico completo es importante para hacer un diagnóstico oportuno con el 
fin de iniciar el tratamiento multidisciplinario y reducir la morbimortalidad.
Palabras clave: enfermedad de Fabry; alfa-galactosidasa; enfermedades por 
almacenamiento lisosómico; opacidad de la córnea; vasos retinianos; cápsula del cristalino.
Fabry disease is a rare X-linked disorder caused by alpha-galactosidase 
deficiency which leads to a progressive lysosomal glycosphingolipids 
accumulation, mainly globotriaosylceramide (Gb3) (1) in endothelial and 
smooth muscle cells of several organs vessels including the eye (1-4).
Clinical manifestations begin during infancy and adolescence and include 
intermittent acroparesthesias (5), limbs chronic pain (3,6), “Fabry crises” 
(1,5), angiokeratomas (5,6), hypo-anhidrosis (5), gastrointestinal and cardiac 
abnormalities (1,5,7,8), cerebrovascular attacks, and ocular abnormalities (2,9,10). 
The disease occurs primarily in the cornea, conjunctiva, lens, and retina. 
Ophthalmological features of Fabry disease have been described not only in 
the anterior segment but also in the posterior pole of the eye. Anterior segment 
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manifestations are aneurysmal vessels in the bulbar conjunctiva, cornea 
verticillata, and opacification of the lens. In the posterior segment, the most 
common features are vessel tortuosity and retinal vascular occlusions (1).
Early diagnosis is important to start a prompt enzyme replacement therapy 
(11,12) and to prevent new ocular complications and irreversible systemic 
organ damage, although enzyme replacement therapy does not reverse the 
established ocular manifestations of Fabry disease (2).
The purpose of this case series is to present the ocular findings of Fabry 
disease in a Colombian series of cases to improve diagnosis, remission, and 
early treatment of these patients, avoiding long-term complications that can 
increase morbidity and mortality.
Case series
Four male patients diagnosed with Fabry disease and a carrier woman, all 
from Bogotá, Colombia, were referred to a reference ophthalmologic center 
for evaluating their ophthalmological features. The diagnosis was previously 
made by geneticists considering the clinical findings by testing for deficient 
α-galactosidase A (α-GAL) enzyme activity and confirmed by DNA analysis of 
the α-GAL A gene. Four patients belonged to the same family: Three brothers 
and the mother identified as patients 1, 2, 3, and 4 (table 1).
All of the patients (or relatives/guardians) signed the assent and/or 
informed consent. A complete clinical record with family and personal history, 
optometric-ophthalmological examination and ocular photographic register of 
anterior and posterior segments of the eye were completed (table 1).
Refractive defects were found in all patients as composed myopic 
astigmatism, three with mixed astigmatism and amblyopia. They all had 
punctate brown-cream corneal deposits with a central corneal radiated 
pattern, which in advanced cases generated a verticillata pattern (figure 1).
Four patients had a wedge shape brown-cream deposit on the anterior internal 
lens capsule periphery, predominantly inferior (figure 2). All of them except for the 
carrier female presented with conjunctival and retinal vessels tortuosity (table 1). 
Four of the five patients presented the ‘classic variant’ of Fabry disease and only 
Case Gender Age
Family 
history 
of Fabry 
disease 
Neuropathy 
Organs 
affected 
besides eye at 
the moment of 
the ophthalmic 
evaluation
Ametropy Ambliopy
Cornea 
verticillata
Lens 
opacity 
Conjuctival 
vascular 
tortuosity
Retinal 
tortuous 
vessels
Lacrimal 
abnormality
1 Male 14 Yes No No Mixed 
astigmatism
Yes Yes Yes Yes Yes No
2 Male 19 Yes Yes No Simple 
myopic 
astigmatism
Yes Yes Yes Yes Yes No
3 Female 38 Yes No No Simple 
myopic 
astigmatism
No Yes No No No No
4 Male 17 Yes Yes No Mixed 
astigmatism
Yes Yes Yes Yes Yes No
5 Male 43 No No Kidney Simple 
myopic 
astigmatism/
mixed 
astigmatism
Yes Yes Yes Yes Yes Yes
Table 1. Demographic, systemic and ophthalmological findings in five Colombian patients with Fabry disease 
436
Rothstein K, Gálvez JM, Gutiérrez AM, et al. Biomédica 2019;39:434-39
Figure 1. Cornea verticillata pattern characterized by brown-cream color deposits in a radiated 
pattern observed in patient 4
Figure 2. Lens opacity described as brown-cream deposits in the periphery of the anterior 
internal capsule of the lens observed in patient 2
one presented the ‘kidney variant’ with severe renal compromise requiring kidney 
transplantation (table 1). The starting time of enzyme replacement therapy was not 
specified in the clinical charts of the patients.
Discussion
Ophthalmological findings are common in Fabry disease compromising 
various ocular structures (1,2,8,9,13). In our case series, one of the most 
typical ocular findings was cornea verticillata pattern found in all of the 
patients; four out of five presented with lens opacity and with tortuosity and 
dilatation of retinal and conjunctival vessels. Although four of five presented 
with tortuous vessels, none of them developed retinal venous-arterial 
occlusions and none presented with optic disc edema.
437
Biomédica 2019;39:434-39 Ocular findings in Fabry disease
Corneal epithelial-subepithelial deposits are the most important ocular 
manifestation (7) presenting in more than 95% of affected males and 88% 
of carrier females. The injury starts during infancy as a diffuse cloud, which 
progresses to cornea verticillata, characterized by radial, linear, symmetric, 
and bilateral cream to brown-gold color deposits (14). 
Cornea verticillata is the most distinctive finding in females. All males in 
our case series presented cornea verticillata, as well as other ocular findings 
such as conjunctiva, lens, and retinal alterations. In contrast, the only woman 
among our patients presented cornea verticillata without the aforementioned 
findings. Cornea verticillata is rare in subjects without Fabry disease and, 
therefore, this finding has high diagnostic sensitivity and specificity, often 
related to disease severity (15).
Other causes of cornea verticillata are amiodarone prolonged therapy, 
aminoquinoline, atovaquone, subconjunctival gentamicin, gold salts, 
ibuprofen, indomethacin, naproxen, phenothiazine, tamoxifen, multiple 
myeloma, and environmental exposure to silica dust (16). All pathologies and/
or drugs that can produce similar findings were discarded in the patients.
Vascular conjunctival abnormalities include vessel dilatation, tortuosity, and 
aneurysms, which are more common in the inferior bulbar conjunctiva (1,14). 
Vascular tortuosity is related with disease severity (17). Similarly, except for the 
female, all of our patients presented with conjunctival abnormalities.
In the literature, lens opacities are present in 70% of males and 35% of 
carrier females. Posterior opacities are the most common in both genders. 
Linear white opacities reveal the Gb3 epithelium deposits through the posterior 
suture lines known as Fabry cataracts, the only ocular diagnostic criteria (1). 
Anterior cataract, seen in 31% of males and 5% of females, is usually bilateral 
and wedge-shaped, with a variable density. Helix form, granular cream color 
deposits are found in the anterior capsule (4,14). According to this, lens 
opacities were observed in all four males of our case series. Figure 2 shows 
the linear-white opacities compatible with Fabry cataract. 
The most common retinal finding is vascular tortuosity (1), found in 77% of 
males and 19% of carrier females. A narrowing of small vessels can cause a 
vascular-occlusive phenomenon secondary to Gb3 accumulation. Therefore, 
Fabry disease should be considered when a young patient presents a retinal 
or peripapillary vascular-occlusive event. Several patients have visual loss 
caused by retinal central artery-vein occlusion, ischemic optic neuropathy, 
optic atrophy, retinal ischemia or choroid perfusion defects (1). Although 
retinal vascular tortuosity was observed in four of our male patients, there 
were no vascular-occlusive events.
Increased blind-spot has been reported without an afferent disc defect or 
dyschromatopsia. Other findings include myopia, nerve fibers myelination, 
and disc edema (14,18). None of our patients had optic nerve alterations. All 
of them presented with refractive errors consistent with astigmatism and three 
of them with myopic astigmatism.
Because most ocular findings do not compromise visual acuity, patients 
rarely consult ophthalmologists. Nevertheless, when a characteristic Fabry 
sign is observed, it should be suspected and referred for a complete screening, 
especially when the patient is young, as in such cases ophthalmologists may 
identify an early-stage disease before complications appear. Ocular signs can 
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act as markers of the disease with diagnostic and prognostic implications. 
As the eye is an external organ easily investigated with minimally invasive 
technologies, it may be useful for monitoring the natural history of Fabry 
disease and its response to enzyme replacement therapy (17).
All the patients in this series were referred to our clinic with the diagnosis 
of Fabry disease for ophthalmological examination and ocular findings were 
present in all of them. 
The clinical systemic presentation is heterogeneous and the signs and 
symptoms change with the age of the patient due to the slow progressiveness 
of the disease (17,19). Three of our patients were male siblings under 20 
years of age who presented with acroparesthesia, neuropathic pain, joint 
and abdominal pain crisis, and dyshidrosis. They did not report cardiac, 
respiratory symptoms or stroke, probably because such symptoms often 
appear at a later age (19). Patient 5, the oldest in the case series (43 years-
old), had a renal variant, several of the symptoms already mentioned, such as 
pain attacks, and was under enzymatic treatment. Additionally, he was taking 
immunosuppressant medications for post-transplant management. 
An exhaustive ophthalmological assessment offers an important opportunity 
for early diagnosis. Any patient with corneal opacity, cornea verticillata or Fabry 
cataract in association with retinal vessels tortuosity, conjunctival telangiectasia 
or lens opacities should have a detailed evaluation and appraisal of family 
history. If there is a high risk of Fabry disease, the patient should be referred to 
a geneticist for evaluation and genetic counseling. If it is confirmed, the patient 
can be treated and multidisciplinary management should be started before 
irreversible complications appear (19). The treatment does not depend only 
on the diagnosis; rather, since each patient is different, the treatment pathway 
should be adjusted and managed according to the individual. 
Greater awareness of Fabry disease among optometrists and 
ophthalmologists could reduce diagnostic delays and decrease early mortality 
of these patients.
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